1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Influenzavirus B Infection Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 APP-309
1.4.3 CF-403
1.4.4 GC-3106A
1.4.5 KIN-1400
1.4.6 Others
1.5 Market by Application
1.5.1 Global Influenzavirus B Infection Drug Market Share by Application: 2021-2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Influenzavirus B Infection Drug Market
1.8.1 Global Influenzavirus B Infection Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Influenzavirus B Infection Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Influenzavirus B Infection Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Influenzavirus B Infection Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Influenzavirus B Infection Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Influenzavirus B Infection Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Influenzavirus B Infection Drug Sales Volume
3.3.1 North America Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Influenzavirus B Infection Drug Sales Volume
3.4.1 East Asia Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.5.1 Europe Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.6.1 South Asia Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.8.1 Middle East Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.9.1 Africa Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.10.1 Oceania Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.11.1 South America Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Influenzavirus B Infection Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Influenzavirus B Infection Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Influenzavirus B Infection Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Influenzavirus B Infection Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Influenzavirus B Infection Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Influenzavirus B Infection Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Influenzavirus B Infection Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Influenzavirus B Infection Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Influenzavirus B Infection Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Influenzavirus B Infection Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Influenzavirus B Infection Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Influenzavirus B Infection Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Influenzavirus B Infection Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Influenzavirus B Infection Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Influenzavirus B Infection Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Influenzavirus B Infection Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Influenzavirus B Infection Drug Consumption Volume by Application (2015-2020)
15.2 Global Influenzavirus B Infection Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Influenzavirus B Infection Drug Business
16.1 AbbVie Inc
16.1.1 AbbVie Inc Company Profile
16.1.2 AbbVie Inc Influenzavirus B Infection Drug Product Specification
16.1.3 AbbVie Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 ContraFect Corp
16.2.1 ContraFect Corp Company Profile
16.2.2 ContraFect Corp Influenzavirus B Infection Drug Product Specification
16.2.3 ContraFect Corp Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Amarillo Biosciences Inc
16.3.1 Amarillo Biosciences Inc Company Profile
16.3.2 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Specification
16.3.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Adimmune Corp
16.4.1 Adimmune Corp Company Profile
16.4.2 Adimmune Corp Influenzavirus B Infection Drug Product Specification
16.4.3 Adimmune Corp Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Cadila Healthcare Ltd
16.5.1 Cadila Healthcare Ltd Company Profile
16.5.2 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Specification
16.5.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Altravax Inc
16.6.1 Altravax Inc Company Profile
16.6.2 Altravax Inc Influenzavirus B Infection Drug Product Specification
16.6.3 Altravax Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Fujifilm Holdings Corporation
16.7.1 Fujifilm Holdings Corporation Company Profile
16.7.2 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Specification
16.7.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 BioCryst Pharmaceuticals Inc
16.8.1 BioCryst Pharmaceuticals Inc Company Profile
16.8.2 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Specification
16.8.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Aphios Corp
16.9.1 Aphios Corp Company Profile
16.9.2 Aphios Corp Influenzavirus B Infection Drug Product Specification
16.9.3 Aphios Corp Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Daiichi Sankyo Company Ltd
16.10.1 Daiichi Sankyo Company Ltd Company Profile
16.10.2 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Specification
16.10.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Medicago Inc
16.11.1 Medicago Inc Company Profile
16.11.2 Medicago Inc Influenzavirus B Infection Drug Product Specification
16.11.3 Medicago Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Novavax Inc
16.12.1 Novavax Inc Company Profile
16.12.2 Novavax Inc Influenzavirus B Infection Drug Product Specification
16.12.3 Novavax Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 GlaxoSmithKline Plc
16.13.1 GlaxoSmithKline Plc Company Profile
16.13.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Specification
16.13.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Romark Laboratories LC
16.14.1 Romark Laboratories LC Company Profile
16.14.2 Romark Laboratories LC Influenzavirus B Infection Drug Product Specification
16.14.3 Romark Laboratories LC Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 MedImmune LLC
16.15.1 MedImmune LLC Company Profile
16.15.2 MedImmune LLC Influenzavirus B Infection Drug Product Specification
16.15.3 MedImmune LLC Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Kineta Inc
16.16.1 Kineta Inc Company Profile
16.16.2 Kineta Inc Influenzavirus B Infection Drug Product Specification
16.16.3 Kineta Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Green Cross Corp
16.17.1 Green Cross Corp Company Profile
16.17.2 Green Cross Corp Influenzavirus B Infection Drug Product Specification
16.17.3 Green Cross Corp Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Park Active Molecules
16.18.1 Park Active Molecules Company Profile
16.18.2 Park Active Molecules Influenzavirus B Infection Drug Product Specification
16.18.3 Park Active Molecules Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 Mucosis BV
16.19.1 Mucosis BV Company Profile
16.19.2 Mucosis BV Influenzavirus B Infection Drug Product Specification
16.19.3 Mucosis BV Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.20 Inovio Pharmaceuticals Inc
16.20.1 Inovio Pharmaceuticals Inc Company Profile
16.20.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Specification
16.20.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.21 Vectura Group Plc
16.21.1 Vectura Group Plc Company Profile
16.21.2 Vectura Group Plc Influenzavirus B Infection Drug Product Specification
16.21.3 Vectura Group Plc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.22 Sanofi
16.22.1 Sanofi Company Profile
16.22.2 Sanofi Influenzavirus B Infection Drug Product Specification
16.22.3 Sanofi Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.23 Vaxart Inc
16.23.1 Vaxart Inc Company Profile
16.23.2 Vaxart Inc Influenzavirus B Infection Drug Product Specification
16.23.3 Vaxart Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.24 TSRL Inc
16.24.1 TSRL Inc Company Profile
16.24.2 TSRL Inc Influenzavirus B Infection Drug Product Specification
16.24.3 TSRL Inc Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.25 SK Chemicals Co Ltd
16.25.1 SK Chemicals Co Ltd Company Profile
16.25.2 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Specification
16.25.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.26 Sanofi Pasteur SA
16.26.1 Sanofi Pasteur SA Company Profile
16.26.2 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Specification
16.26.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.27 Shionogi & Co Ltd
16.27.1 Shionogi & Co Ltd Company Profile
16.27.2 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Specification
16.27.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Influenzavirus B Infection Drug Manufacturing Cost Analysis
17.1 Influenzavirus B Infection Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Influenzavirus B Infection Drug
17.4 Influenzavirus B Infection Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Influenzavirus B Infection Drug Distributors List
18.3 Influenzavirus B Infection Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Influenzavirus B Infection Drug (2021-2026)
20.2 Global Forecasted Revenue of Influenzavirus B Infection Drug (2021-2026)
20.3 Global Forecasted Price of Influenzavirus B Infection Drug (2015-2026)
20.4 Global Forecasted Production of Influenzavirus B Infection Drug by Region (2021-2026)
20.4.1 North America Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Influenzavirus B Infection Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Influenzavirus B Infection Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.2 East Asia Market Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.3 Europe Market Forecasted Consumption of Influenzavirus B Infection Drug by Countriy
21.4 South Asia Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.5 Southeast Asia Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.6 Middle East Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.7 Africa Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.8 Oceania Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.9 South America Forecasted Consumption of Influenzavirus B Infection Drug by Country
21.10 Rest of the world Forecasted Consumption of Influenzavirus B Infection Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer